Title: New Insights about the Glycan Ligands of Siglecs and their Ability to Control Immune Cells
The primary focus of Dr. Matthew Macauley’s laboratory is the immunomodulatory sialic acid-binding Siglec family of receptors. His group develops innovative approaches to probe Siglec-glycan interactions on cells and tissues and use new insights about the biological ligands of Siglecs to test hypotheses about the roles of Siglecs in controlling immune cell function.
Title: Rethinking the Paradigm: New Roles for Non-Coding RNA in Controlling the Cancer Glycome.
Dr. Lara K. Mahal is the Canada Excellence Research Chair in Glycomics and a Professor of Chemistry at the University of Alberta. Her work focuses on systems-based approaches to understanding glycans, complex sugars that encode information governing human health. She developed lectin microarray technology, a high-throughput method for analyzing glycans that is now widely applied to understand the role of these sugars in a multitude of systems, from clinical cancer research to host-pathogen interactions. She is also known for her ground-breaking work on microRNA regulation, including the discovery of upregulation as a common feature of the miRNA regulatory landscape. She is the recipient of numerous awards, including the Beckman Foundation Fellowship (2004), NSF CAREER Award (2007), Sloan Foundation Fellowship (2008), NIH Director’s New Innovator Award (2008), the Horace S. Isbell Award (2017) and the Canada Excellence Research Chair in Glycomics (2019). In 2022, she founded the Glycomics Institute of Alberta (GIA) at the University of Alberta.
The research activity of Professor De Castro is in carbohydrate structural chemistry, and her training in this subject started during her bachelor thesis, which focused on plant polysaccharides. Since then, even though Professor De Castro continued her work on carbohydrate structural chemistry, she shifted her interests and dedicated her activity to the analysis of the bacterial membrane carbohydrate components, paying attention, but not limiting the work, to Gram-negative bacteria and lipopolysaccharides (LPSs). This work has resulted in the development of state-of-the-art chemical and spectroscopical approaches that have been later applied with success to different kinds of carbohydrates, such as those from the bacteria of the gut microbiota or those from the giant viruses. This last topic is Professor De Castro's major field of research.
Professor De Castro is the author/co-author of about 130 peer-reviewed publications, an associated Editor for the journal Carbohydrate Polymers, and a member of the editorial board of Carbohydrate Research, Glycobiology, and Polysaccharides. She fruitfully collaborates with different research institutions, such as the Department of Plant Pathology (University of Nebraska Lincoln, NE, USA) and the Structural and Genomics Information Laboratory in Marseille (France).
Title: Making weak antigens strong: exploiting bacterial outer membrane vesicles for delivering glycans to the immune system
Professor Matthew P. DeLisa is the William L. Lewis Professor of Engineering in the School of Chemical and Biomolecular Engineering at Cornell University. His research focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis--folding and assembly, membrane translocation, and post-translational modifications--in the complex environment of a living cell. He received a B.S. in Chemical Engineering from the University of Connecticut in 1996; a Ph.D. in Chemical Engineering from the University of Maryland in 2001; and postdoctoral work at the University of Texas-Austin, Department of Chemical Engineering. DeLisa joined the Department of Chemical and Biomolecular Engineering at Cornell University in 2003. He has also served as a Gastprofessur at the Swiss Federal Institute of Technology (ETH Zürich) in the Institut für Mikrobiologie. He has garnered a number of honors and awards, including most recently the Biotechnology Progress Award for Excellence in Biological Engineering Publication, and was named the to the inaugural “Life Sciences Power 50” by City & State New York. He is an elected fellow of the American Institute for Medical and Biological Engineering, the American Academy of Microbiology, and the American Association for the Advancement of Science. In recent years, he has served on the IDA/DARPA Defense Science Study Group and the National Academies Committee on Innovative Technologies to Advance Pharmaceutical Manufacturing.
Title: Molecular Signals Controlling the Biosynthesis and Biological Activities of Cell Envelope (Lipo)Polysaccharides in Mycobacterium tuberculosis
Dr. Mary Jackson is currently a Professor of Bacteriology in the Department of Microbiology, Immunology, and Pathology at Colorado State University. She earned a Bioengineering degree and an MSc. Degree from the National School of Agronomy, Rennes, France, in 1994, and a Ph.D. in Biochemistry and Cellular and Molecular Biology from the Pasteur Institute, Paris, France, in 1998.
Her research focuses on the elucidation of critical pathways leading to the biosynthesis and export of (glyco)lipids, fatty acids, and polysaccharides in Mycobacterium tuberculosis and other mycobacterial pathogens of clinical interest to inform novel therapeutic strategies.
Dr. Jackson has published over 185 peer-reviewed scientific articles and serves on numerous grant review panels for the National Institutes of Health and other Federal, private, and non-profit funding agencies globally.
Title: Quantitative descriptions of structure-function relationships of glycoSHIELD of coronavirus spike proteins
Dr. Danny Hsu is a Research Fellow at the Institute of Biological Chemistry, Academia Sinica. During his doctorate study at Utrecht University, the Netherlands, he determined the atomic structure of a lantibiotic, nisin, in complex with Gram-positive bacterial cell wall precursor, Lipid II. He coined the term "pyrophosphate case" to explain how nisin targets Lipid II to achieve its antimicrobial activity, providing a blueprint for future antibiotics developments. During his postdoctoral research at the University of Cambridge, UK, Danny demonstrated the proof of concept of using solution-state NMR spectroscopy to investigate the co-translational folding of nascent polypeptide chains on the ribosome. His earlier independent research focused on the folding mechanisms and functional implications of topologically knotted proteins. He currently focuses on developing an integrated biophysics and structural biology platform, including cryo-electron microscopy, mass spectrometry, and molecular modeling, to investigate the structure-activity relationship (SAR) of glycoproteins, and coronavirus spike proteins, in particular, and how mutations impact on the SAR in the context of glycosylation.
Title: Genome-wide Analysis of Heparan Sulfate Assembly
Dr. Ryan Weiss began his diverse scientific training by earning his B.S. in Chemistry in 2008 at Point Loma Nazarene University in San Diego, CA, USA. He then received his Ph.D. in Chemistry in 2015 at the University of California, San Diego, under the supervision of Prof. Yitzhak Tor, where he studied the design, synthesis, and application of small molecule antagonists of heparin- and heparan sulfate-protein interactions. As an NIH K12 postdoctoral fellow in Prof. Jeffrey Esko’s group at the Department of Cellular and Molecular Medicine at the University of California, San Diego, his research focused on utilizing whole-genome screening methods to investigate the regulation of heparan sulfate biosynthesis. Dr. Weiss began his independent career as an assistant professor at the Complex Carbohydrate Research Center at the University of Georgia in January 2021. Research in the Weiss Laboratory focuses on studying the structure, function, and regulation of complex carbohydrates in human biology and disease. In addition, his lab is dedicated to developing pharmacological and cell-based tools to aid in the discovery of novel targets and approaches for modulating glycan assembly in relevant human disorders.
Title: Build it to understand it: O-GlcNAc modification plays multiple protective roles against protein amyloid aggregation and pathogenesis
Professor Matthew Pratt received a B.S. in Biochemistry and Mathematics from the University of Arizona in 1999, where he worked for Robin Polt on glycosylation reactions and the synthesis of glycosylated analogs of enkephalin peptides. He then moved to Carolyn Bertozzi' s lab at the University of California Berkeley and focused on the synthesis of complex carbohydrates and the development of chemical tools to analyze glycosylation, receiving a Ph.D. in Chemistry in 2004. He was then an American Cancer Society Postdoctoral Fellow in Tom Muir' s lab at Rockefeller University, where he developed technologies to control proteins in living cells and for the incorporation of modifications into semi-synthetic proteins. He joined the faculty at the Department of Chemistry and Biological Sciences at USC in 2009. His research focuses on the development of bioorthogonal chemical reporters and synthetic proteins to investigate the role of posttranslational modifications, with a particular interest in O-GlcNAc modification.
Title: Desialylation GlycoSwitch to Acutely Control Endocytosis
Professor Ludger Johannes is Research Director (DRE) at INSERM. He is a member of the Studienstiftung des Deutschen Volkes (German organization of the academically gifted), Boehringer Ingelheim Fonds, European Molecular Biology Organization (EMBO), and German Academy of Science — Leopoldina. At Institut Curie, he has been heading since 2001 the Traffic, Signaling, and Delivery Team, member of the excellence initiative Cell(n)Scale. Since January 2014, he has directed the Cellular and Chemical Biology unit. His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking. The Johannes team has discovered the membrane trafficking interface between early endosomes and the Golgi apparatus, and demonstrated that lectin-induced glycolipid reorganization acts as a driving force in clathrin-independent endocytosis (termed the GlycoLipid-Lectin / GL-Lect hypothesis). The studies of the Johannes team have been published in highly visible international journals, including Cell and Nature. Between 2014-2020, he was the holder of an ERC advanced grant. He also aims at exploiting the discoveries of his team for the development of innovative cancer therapy strategies using the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy.
Title: Mucin Glycans in the Regulation of Microbial Virulence
Professor Ribbeck obtained her Bachelor’s degree and her Ph.D. in Biology from the University of Heidelberg, Germany. She continued her postdoctoral research at the European Molecular Biology Laboratory, Heidelberg, Germany, and the Department of Systems Biology, Harvard Medical School. Professor Ribbeck established her independent research group as a Bauer Fellow at the FAS Center for Systems Biology, Harvard University, in 2007 and joined the Department of Biological Engineering at MIT as an Assistant Professor in 2010.
Her laboratory studies the basic mechanisms of biological hydrogels by which mucus barriers exclude, or allow passage of different molecules and pathogens, and the mechanisms pathogens have evolved to penetrate mucus barriers. It hopes to provide the foundation for a theoretical framework that captures general principles governing selectivity in mucus, and likely other biological hydrogels such as the extracellular matrix, and bacterial biofilms. Her Lab’s work may also be the basis for the reconstitution of synthetic gels that mimic the basic selective properties of biological gels.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.